J. R. Bianchine, M.D.; M. J. T. Peaston, M.D.
This content is PDF only. Please click on the PDF icon to access.
The therapeutic efficacy of large oral doses of L-3:4 dihydroxyphenylalanine (DOPA) in selected patients with Parkinson's disease has been made clear by Cotzias and others. The purpose of this study is to determine the metabolic fate of orally administered L-DOPA. Six men with uncomplicated Parkinson's disease were selected for study. All patients were hospitalized and fasted overnight prior to study. A gelatin capsule containing 100 µc L-[C14]-DOPA (Hoffman-La Roche) labelled in beta position and a total of 500 mg L-DOPA were administered orally at time zero. Serum, expired air, urine, and stool were sampled, first at hourly, then at longer
J. R. Bianchine, M. J. T. Peaston. Metabolism of Orally Administered L-(C14)-DOPA in Patients with Parkinson's Disease.. Ann Intern Med. 1970;72:806. doi: 10.7326/0003-4819-72-5-806_1
Download citation file:
Published: Ann Intern Med. 1970;72(5):806.
Copyright © 2017 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use